Form 4: West Pharmaceutical Services Director Acquires Shares

Mark A. Buthman, a director at West Pharmaceutical Services, acquired 1,071 shares of common stock on May 6, 2025.

Summary

• On May 6, 2025, Mark A. Buthman, a director of West Pharmaceutical Services Inc., acquired 1,071 shares of common stock.
• The acquisition was a direct transaction.
• Following the transaction, Buthman directly owns 42,860.9294 shares of West Pharmaceutical Services Inc.
• The shares of restricted stock units will vest in full on the date of the next annual shareholder meeting.
• A power of attorney was executed on May 15, 2024, granting Luis Cantarero, Louis Lalli, Ryan Metz, and Caitlin Hippeli the authority to file SEC forms on Buthman's behalf.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of share acquisition by a director. The acquisition itself could be seen as slightly positive, but the document is primarily informational.

Positives

• A director increasing their holdings could be seen as a positive signal about their confidence in the company's future.

Future Outlook

The restricted stock units will vest in full on the date of the next annual shareholder meeting.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Form 4, Beneficial Ownership, Director, West Pharmaceutical Services, Share Acquisition, Buthman, WST, Securities